FY2016 Earnings Forecast for Dipexium Pharmaceuticals Inc. (DPRX) Issued By Feltl & Co.
Dipexium Pharmaceuticals Inc. (NASDAQ:DPRX) – Stock analysts at Feltl & Co. raised their FY2016 earnings estimates for shares of Dipexium Pharmaceuticals in a note issued to investors on Monday. Feltl & Co. analyst B. Haynor now anticipates that the firm will post earnings per share of ($1.88) for the year, up from their previous forecast of ($1.93). Feltl & Co. has a “Hold” rating on the stock. Feltl & Co. also issued estimates for Dipexium Pharmaceuticals’ Q4 2016 earnings at ($0.35) EPS.
Other equities research analysts have also issued reports about the stock. Raymond James Financial Inc. lowered shares of Dipexium Pharmaceuticals from an “outperform” rating to a “mkt perform” rating in a report on Wednesday, October 26th. Zacks Investment Research raised shares of Dipexium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a report on Friday, October 28th.
Shares of Dipexium Pharmaceuticals (NASDAQ:DPRX) opened at 1.40 on Wednesday. The company’s market capitalization is $14.56 million. The firm’s 50-day moving average price is $8.00 and its 200-day moving average price is $10.75. Dipexium Pharmaceuticals has a 12-month low of $1.15 and a 12-month high of $17.75.
Large investors have recently bought and sold shares of the company. BlackRock Fund Advisors raised its stake in Dipexium Pharmaceuticals by 19.6% in the second quarter. BlackRock Fund Advisors now owns 15,674 shares of the company’s stock valued at $155,000 after buying an additional 2,568 shares during the last quarter. Wells Fargo & Company MN raised its stake in Dipexium Pharmaceuticals by 263.6% in the third quarter. Wells Fargo & Company MN now owns 12,000 shares of the company’s stock valued at $174,000 after buying an additional 8,700 shares during the last quarter. Ardsley Advisory Partners purchased a new stake in Dipexium Pharmaceuticals during the third quarter valued at about $178,000. State Treasurer State of Michigan purchased a new stake in Dipexium Pharmaceuticals during the third quarter valued at about $181,000. Finally, Raymond James & Associates purchased a new stake in Dipexium Pharmaceuticals during the second quarter valued at about $312,000. 24.57% of the stock is currently owned by institutional investors and hedge funds.
Dipexium Pharmaceuticals Company Profile
Dipexium Pharmaceuticals, Inc is a late-stage pharmaceutical company. The Company is focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a first-in-class, broad spectrum, topical antibiotic. Locilex is focused on the treatment of mild infections of diabetic foot ulcers (Mild DFI).
Receive News & Stock Ratings for Dipexium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dipexium Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.